PFE vs. TEM: Pfizer vs. Tempus AI Stock Comparison

Company Profile

Pfizer (PFE) and Tempus AI (TEM) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but PFE is classified in Pharmaceuticals while TEM is classified in Life Sciences Tools & Services.

Pfizer (PFE) carries decades of public-market history since June 1, 1972, while Tempus AI (TEM) listed on June 14, 2024 — long-window comparisons have far more historical data on the PFE side.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Tempus AI (TEM) has a highly aggressive beta of 3.34, indicating much higher sensitivity to broad-market moves, while Pfizer (PFE) is defensive at 0.35 and tends to be less market-sensitive — a wide gap in beta profiles.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Tempus AI (TEM) reports a negative ROE of -37.55%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Pfizer (PFE) reports 4.47%, ranking against industry peers normally.

Tempus AI (TEM) reports a negative net margin of -12.54%, usually indicating a net loss over the period. Meanwhile Pfizer (PFE) reports 6.34%, ranking against industry peers normally.

Tempus AI (TEM) reports a negative operating margin of -13.82%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Pfizer (PFE) reports 33.38%, ranking against industry peers normally.

Profitability Metrics

Growth

Tempus AI (TEM) at 83.41% sits in the top revenue growth quartile, while Pfizer (PFE) at -1.65% is in the bottom quartile, showing a clear gap in revenue momentum.

Only one side can be read here: Pfizer (PFE) reports EPS growth of -3.55%, ranked against its industry; Tempus AI (TEM) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Tempus AI (TEM) at 2.61 keeps current ratio within its industry’s typical mid-range, while Pfizer (PFE) at 1.42 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for PFE.

Both balance sheets lean debt-heavy versus peers, but TEM is more stretched: Pfizer (PFE) at 0.71 sits in the higher-leverage quartile and Tempus AI (TEM) at 2.86 is above its industry benchmark range.

Financial Strength Metrics

Dividends

Tempus AI (TEM) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Pfizer (PFE) reports a yield of 7.30%, ranking against industry peers normally.

Pfizer (PFE) reports payout ratio above 100% at 245.71%, meaning dividends exceeded current-period earnings; Tempus AI (TEM) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Pfizer (PFE) trades at 41.99 times trailing earnings, ranked against its peers, while Tempus AI (TEM) has no P/E ratio this period.

Pfizer (PFE) at 2.63 sits in the cheaper P/S ratio quartile while Tempus AI (TEM) at 9.19 prices around its industry’s middle — PFE costs less per dollar of sales, though read it alongside growth and margins.

Pfizer (PFE) at 1.88 sits near its industry’s typical P/B ratio, while Tempus AI (TEM) at 27.66 prices above its benchmark range — TEM looks rich relative to book.

Valuation Metrics